Full Title
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive MeningiomaPurpose
Researchers want to see how well cabozantinib works to treat meningioma, a type of brain tumor. The people in this study have meningiomas that came back or keep growing even after treatment.
Cabozantinib is already used to treat other types of cancer. It is a tyrosine kinase inhibitor (TKI). TKIs are drugs that block the action of enzymes called tyrosine kinases. Tyrosine kinases may be too active or found at high levels in some types of cancer cells.
By blocking these enzymes, cabozantinib may help slow or stop the growth of your cancer. This drug is taken orally (by mouth).
Contact
For more information or to see if you can join this study, please call Dr. Thomas Kaley’s office at 212-639-5122.
Protocol
24-325
Phase
Phase II (phase 2)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05425004
ClinicalTrials.gov